Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.15 Insider Own0.40% Shs Outstand93.00M Perf Week-3.25%
Market Cap719.82M Forward P/E- EPS next Y-1.29 Insider Trans9.52% Shs Float81.03M Perf Month0.78%
Income-167.10M PEG- EPS next Q-0.41 Inst Own59.00% Short Float17.80% Perf Quarter-1.15%
Sales0.20M P/S3599.10 EPS this Y-20.40% Inst Trans0.07% Short Ratio9.47 Perf Half Y75.11%
Book/sh0.24 P/B32.25 EPS next Y18.40% ROA-146.50% Target Price19.00 Perf Year-32.40%
Cash/sh0.99 P/C7.79 EPS next 5Y- ROE-308.90% 52W Range3.32 - 12.90 Perf YTD88.78%
Dividend- P/FCF- EPS past 5Y-23.30% ROI-723.70% 52W High-40.00% Beta2.35
Dividend %- Quick Ratio1.70 Sales past 5Y-0.10% Gross Margin- 52W Low133.13% ATR0.40
Employees102 Current Ratio1.70 Sales Q/Q0.00% Oper. Margin- RSI (14)48.36 Volatility3.57% 5.95%
OptionableYes Debt/Eq0.00 EPS Q/Q26.30% Profit Margin- Rel Volume0.64 Prev Close7.97
ShortableYes LT Debt/Eq1.47 EarningsAug 09 BMO Payout- Avg Volume1.52M Price7.74
Recom1.70 SMA20-2.91% SMA503.77% SMA20026.21% Volume968,864 Change-2.89%
Feb-06-19Resumed Jefferies Buy $8
Sep-25-18Downgrade Raymond James Strong Buy → Outperform
Mar-09-18Reiterated B. Riley FBR, Inc. Buy $21.50 → $27
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Jul-09-19 10:43PM  Edited Transcript of TGTX earnings conference call or presentation 10-May-19 12:00pm GMT Thomson Reuters StreetEvents
Jul-05-19 05:14PM  Heres What Hedge Fund Think About TG Therapeutics Inc (TGTX) Insider Monkey
Jul-02-19 07:30AM  TG Therapeutics Announces Presentation of Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis During an Oral Session at the 5th Congress of the European Academy of Neurology GlobeNewswire
Jun-30-19 11:46PM  Weekly CEO Buys Highlight GuruFocus.com
Jun-27-19 12:27PM  Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +14.33%
Jun-18-19 07:30AM  TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference GlobeNewswire
Jun-17-19 07:30AM  TG Therapeutics Presents Preclinical Data for TG-1801, a First-in-Class Anti-CD47/CD19 Bispecific Antibody, at the 24th European Hematology Association Annual Congress GlobeNewswire
Jun-11-19 07:58AM  TG Therapeutics Confirms Registration Path for Umbralisib in Marginal Zone Lymphoma Following FDA Meeting GlobeNewswire
Jun-04-19 04:02PM  TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
07:30AM  TG Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-28-19 09:28AM  TG Therapeutics May Have Potential but the Charts Need More Work TheStreet.com
May-23-19 07:20PM  TG Therapeutics CEO: Going through the process to reach big markets CNBC Videos
May-16-19 07:30AM  TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings GlobeNewswire
May-10-19 01:23PM  TG Therapeutics Inc (TGTX) Q1 2019 Earnings Call Transcript Motley Fool -6.78%
07:31AM  TG Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
May-09-19 07:30AM  TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update GlobeNewswire
May-07-19 09:00AM  TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting GlobeNewswire -5.68%
Apr-17-19 11:13AM  Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings? Zacks
Apr-16-19 09:28PM  Is TG Therapeutics a Buy? Motley Fool
03:17PM  Did TG Therapeutics, Inc. (NASDAQ:TGTX) Insiders Sell Shares? Simply Wall St.
Apr-15-19 07:30AM  TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma GlobeNewswire
Apr-10-19 01:40PM  5 Oncology Companies That Are Set to Run GuruFocus.com +5.12%
Apr-08-19 10:00AM  3 Top Biotech Stocks to Buy in April Motley Fool
Apr-02-19 09:27AM  Company News For Apr 2, 2019 Zacks
Apr-01-19 01:46PM  TG Therapeutics Breaks Out on Positive Umbralisib Data Investopedia
08:46AM  Is the Options Market Predicting a Spike in TG Therapeutics (TGTX) Stock? Zacks
08:30AM  TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting GlobeNewswire
Mar-29-19 04:00PM  TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting GlobeNewswire +7.77%
Mar-12-19 08:00AM  TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting GlobeNewswire
Mar-11-19 10:43AM  What Makes TG Therapeutics (TGTX) a New Strong Buy Stock Zacks +5.96%
07:26AM  TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference GlobeNewswire
Mar-08-19 07:30AM  TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials GlobeNewswire
Mar-06-19 01:29PM  Those Who Purchased TG Therapeutics Shares A Year Ago Have A 57% Loss To Show For It Simply Wall St.
Mar-04-19 08:02AM  This Is Why TG Therapeutics Stock Soared 65.9% in February Motley Fool -5.27%
Mar-01-19 10:27AM  The Meet Group (MEET) to Report Q4 Earnings: What's in Store? Zacks +6.03%
09:00AM  TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings GlobeNewswire
08:50AM  The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis Benzinga
08:30AM  3 Recent Big Gainers Kick Off the Dramatic Return of 'Small-Cap Friday' TheStreet.com
08:00AM  Why These Pharma ETFs Rallied on Thursday Zacks
07:30AM  TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting GlobeNewswire
Feb-28-19 04:10PM  Why TG Therapeutics Stock Skyrocketed 30.5% Today Motley Fool +31.02%
04:01PM  TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing GlobeNewswire
07:00AM  TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma GlobeNewswire
Feb-26-19 09:41AM  Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4? Zacks
07:30AM  TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma GlobeNewswire
Feb-22-19 07:30AM  TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting GlobeNewswire
Feb-20-19 09:45AM  Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings Zacks
Feb-18-19 09:06AM  HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store? Zacks
Feb-15-19 08:54AM  Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings Zacks
Feb-11-19 09:19AM  Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings? Zacks +7.11%
Jan-30-19 09:15AM  TG Therapeutics (TGTX) Upgraded to Buy: Here's What You Should Know Zacks
07:30AM  TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase I Triple Therapy Combination Trial of Ublituximab, Umbralisib, and Ibrutinib in The Lancet Haematology GlobeNewswire
Jan-28-19 09:30AM  Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year? Zacks -7.67%
Jan-22-19 01:07PM  Do Insiders Own Shares In TG Therapeutics, Inc. (NASDAQ:TGTX)? Simply Wall St.
07:30AM  TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma GlobeNewswire
Jan-15-19 09:00AM  Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher Zacks
Jan-11-19 03:51PM  Edited Transcript of TGTX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Jan-07-19 07:30AM  TG Therapeutics, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:20AM  Market Trends Toward New Normal in Brunswick, Atkore International Group, TG Therapeutics, Las Vegas Sands, Benchmark Electronics, and ProPetro Holding Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-31-18 08:49AM  The Most Promising Biotech Names Heading Into 2019 Investopedia
Dec-30-18 01:39PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire
Dec-27-18 10:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX ACCESSWIRE
Dec-21-18 05:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire -7.22%
Dec-19-18 10:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX ACCESSWIRE -8.29%
Dec-18-18 08:35AM  5 Beaten-Down Medical Product Stocks to Rebound in 2019 Zacks -5.17%
02:08AM  Hedge Funds Are Buying TG Therapeutics Inc (TGTX) Insider Monkey
Dec-17-18 07:30AM  TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology GlobeNewswire -6.32%
Dec-14-18 08:26PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire -5.00%
Dec-12-18 07:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX ACCESSWIRE
08:19AM  3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019 Motley Fool
07:35AM  Recent Analysis Shows Verizon Communications, MGM Resorts International, Exelon, Axon Enterprise, M.D.C., and TG Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Dec-07-18 05:18PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire
Dec-05-18 06:01PM  Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Trevena, Inc. GlobeNewswire
Dec-04-18 02:46PM  Is TG Therapeutics Incs (NASDAQ:TGTX) CEO Overpaid Relative To Its Peers? Simply Wall St.
02:18PM  Edited Transcript of TGTX earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
07:30AM  TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Dec-03-18 12:29PM  CLASS ACTION DEADLINE for TGTX, ACHC and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:09AM  DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:00AM  FINAL DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018 GlobeNewswire
07:30AM  TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richters Transformation at 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Dec-02-18 03:00PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acadia, TG Therapeutics, Namaste, and Huazhu Group and Encourages Investors to Contact the Firm GlobeNewswire
11:00AM  DEADLINE MONDAY: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ACHC and ADNT GlobeNewswire
Nov-30-18 05:41PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX GlobeNewswire
01:43PM  CLASS ACTION UPDATE for TGTX, ACHC and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:49PM  MONDAY DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
07:30AM  TG Therapeutics, Inc. Recaps Triple Therapy Data Presentations at the Upcoming 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-29-18 06:18PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In TG Therapeutics, Inc. To Contact The Firm GlobeNewswire
02:08PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ACHC, JT, HTHT and ATUS GlobeNewswire
01:34PM  MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:32AM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018 ACCESSWIRE
Nov-28-18 05:55PM  SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
11:02AM  Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against TG Therapeutics, Inc. (TGTX) and December 3 Lead Plaintiff Deadline Business Wire
10:45AM  MONDAY DEADLINE: Kaskela Law LLC Announces Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm TGTX GlobeNewswire
10:00AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018 GlobeNewswire
Nov-27-18 08:26PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Optoelectronics, Acadia Healthcare, and TG Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire
02:05PM  SHAREHOLDER ALERT: APOG TGTX JT COST HON DY RYAAY MGI PPDF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
08:20AM  Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-26-18 09:05PM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against TG Therapeutics, Inc. Investors (TGTX) Business Wire
06:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TG Therapeutics, Inc. - TGTX ACCESSWIRE
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Power Sean ACFO, Secretary and TreasurerJul 01Sale8.4717,654149,529383,338Jul 03 04:00 PM
WEISS MICHAEL SCEO and PresidentJun 26Buy7.0450,000351,75012,878,185Jun 27 07:33 AM
Power Sean ACFO, Secretary and TreasurerJan 02Sale4.1337,275153,946400,992Jan 03 07:21 PM